PE20070714A1 - Solucion de cloruro de sodio para reconstitucion o dilucion de farmaco - Google Patents

Solucion de cloruro de sodio para reconstitucion o dilucion de farmaco

Info

Publication number
PE20070714A1
PE20070714A1 PE2006001318A PE2006001318A PE20070714A1 PE 20070714 A1 PE20070714 A1 PE 20070714A1 PE 2006001318 A PE2006001318 A PE 2006001318A PE 2006001318 A PE2006001318 A PE 2006001318A PE 20070714 A1 PE20070714 A1 PE 20070714A1
Authority
PE
Peru
Prior art keywords
formulation
around
dilution
sodium chloride
chloride solution
Prior art date
Application number
PE2006001318A
Other languages
English (en)
Inventor
Julie Zerfas
Chandra A Webb
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37801586&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20070714(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PE20070714A1 publication Critical patent/PE20070714A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE A UNA PREPARACION DE UNA FORMULACION FARMACEUTICA PARA INYECCION INTRAVENOSA CARACTERIZADA PORQUE DICHA FORMULACION ES CASI ISOTONICA CON RESPECTO AL PLASMA Y TIENE UNA OSMOLARIDAD DE 220 mOsm/L HASTA ALREDEDOR DE 270 mOsm/L; ADEMAS TIENE UNA FUERZA IONICA DE 36 mEq/LDE IONES Na Y Cl. LA FORMULACION A SER PREPARADA PARA INYECCION ES UNA FORMULACION LIOFILIZADA O SOLUCION. UNA FORMULACION DE LA INVENCION COMPRENDE UNA TORTA LIOFILZADA QUE CONTIENE: A) 10 mM DE HISTIDINA; B) 0.26M DE GLICINA; C) ALREDEDOR DE 1% DE SACAROSA; D) ALREDEDOR DE 0.005% DE POLISORBATO 80; E) DESDE ALREDOR DE 50 IU/mL HASTA ALREDOR DE 2000 IU (mL DE FACTOR IX). DICHAS FORMULACIONES IMPIDEN LA AGLUTINACION DE ERITROCITOS CAUSADOS POR SOLUCIONES DE BAJA FUERZA IONICA AL CONTACTO CON LA SANGRE
PE2006001318A 2005-11-01 2006-10-27 Solucion de cloruro de sodio para reconstitucion o dilucion de farmaco PE20070714A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US73222105P 2005-11-01 2005-11-01

Publications (1)

Publication Number Publication Date
PE20070714A1 true PE20070714A1 (es) 2007-07-20

Family

ID=37801586

Family Applications (3)

Application Number Title Priority Date Filing Date
PE2015001729A PE20151284A1 (es) 2005-11-01 2006-10-27 Solucion de cloruro de sodio para reconstitucion o dilucion de farmaco
PE2006001318A PE20070714A1 (es) 2005-11-01 2006-10-27 Solucion de cloruro de sodio para reconstitucion o dilucion de farmaco
PE2011000653A PE20110803A1 (es) 2005-11-01 2006-10-27 Solucion de cloruro de sodio para reconstitucion o dilucion de farmaco

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2015001729A PE20151284A1 (es) 2005-11-01 2006-10-27 Solucion de cloruro de sodio para reconstitucion o dilucion de farmaco

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2011000653A PE20110803A1 (es) 2005-11-01 2006-10-27 Solucion de cloruro de sodio para reconstitucion o dilucion de farmaco

Country Status (31)

Country Link
US (4) US20070135343A1 (es)
EP (3) EP1942868B2 (es)
JP (1) JP5555425B2 (es)
KR (2) KR101126670B1 (es)
CN (1) CN101351190B (es)
AR (2) AR056748A1 (es)
AU (1) AU2006308921C1 (es)
BR (1) BRPI0618133A2 (es)
CA (1) CA2626531C (es)
CR (1) CR9958A (es)
DK (2) DK3225233T3 (es)
EC (1) ECSP088485A (es)
ES (2) ES2627684T5 (es)
FI (1) FI1942868T4 (es)
FR (1) FR20C1005I1 (es)
GT (1) GT200800037A (es)
HK (1) HK1245090B (es)
HU (4) HUE033949T2 (es)
IL (1) IL190843A (es)
LU (1) LUC00035I2 (es)
MY (1) MY184364A (es)
NO (1) NO347263B1 (es)
NZ (1) NZ567685A (es)
PE (3) PE20151284A1 (es)
PL (2) PL3225233T3 (es)
PT (2) PT3225233T (es)
RU (1) RU2432157C2 (es)
SI (2) SI3225233T1 (es)
TW (1) TWI480063B (es)
UA (1) UA97234C2 (es)
WO (1) WO2007053533A2 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1942868B2 (en) 2005-11-01 2023-10-04 Wyeth LLC Sodium chloride solution for drug reconstitution or dilution
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
US8431011B2 (en) * 2008-01-31 2013-04-30 Abbott Diabetes Care Inc. Method for automatically and rapidly distinguishing between control and sample solutions in a biosensor strip
AU2010321225B2 (en) * 2009-11-17 2015-12-03 Ipsen Pharma S.A.S. Formulation for hGH and rhIGF-1 combination
US9427186B2 (en) 2009-12-04 2016-08-30 Endomagnetics Ltd. Magnetic probe apparatus
US10634741B2 (en) 2009-12-04 2020-04-28 Endomagnetics Ltd. Magnetic probe apparatus
MY182680A (en) 2010-01-15 2021-01-29 Amgen K A Inc Antibody formulation and therapeutic regimens
US9956165B2 (en) * 2010-03-01 2018-05-01 Cytodyn Inc. Concentrated protein formulations and uses thereof
KR20230156435A (ko) 2010-07-09 2023-11-14 바이오버라티브 테라퓨틱스 인크. 인자 iｘ 폴리펩티드 및 이들의 사용 방법
TWI810729B (zh) * 2012-09-25 2023-08-01 美商百歐維拉提夫治療公司 Ｆｉｘ多肽的應用
WO2014140543A1 (en) 2013-03-11 2014-09-18 Endomagnetics Ltd. Hypoosmotic solutions for lymph node detection
US9239314B2 (en) 2013-03-13 2016-01-19 Endomagnetics Ltd. Magnetic detector
US9234877B2 (en) 2013-03-13 2016-01-12 Endomagnetics Ltd. Magnetic detector
AU2014228938B2 (en) * 2013-03-15 2019-05-02 Bioverativ Therapeutics Inc. Factor IX polypeptide formulations
FR3005420B1 (fr) 2013-05-07 2015-09-18 Erytech Pharma Procede de stabilisation de suspensions d'erythrocytes encapsulant un principe actif, suspensions obtenues.
MX2016012447A (es) * 2014-03-24 2017-01-06 Biogen Ma Inc Formulaciones de factor ix liofilizadas.
US9351945B1 (en) 2015-02-27 2016-05-31 John Daniel Dobak, III Reduction of adipose tissue
GB2536703B (en) * 2015-03-27 2020-12-02 Ge Healthcare Bio Sciences Ab Method for baseline correction in a chromatogram
EP3081942A1 (en) * 2015-04-17 2016-10-19 Roche Diagniostics GmbH Pressure transmission liquid for cellular analyzer, cellular analyzer and method for analyzing a liquid cellular sample
ES2833377T3 (es) 2015-06-04 2021-06-15 Endomagnetics Ltd Materiales marcadores y formas de localizar un marcador magnético
US10124021B2 (en) * 2016-12-23 2018-11-13 Andrew L. Gostine Intravenous fluid
CN111295094A (zh) 2017-10-09 2020-06-16 泰尔茂比司特生物技术有限公司 冻干容器及使用冻干容器的方法
JP2022525398A (ja) 2019-03-14 2022-05-13 テルモ ビーシーティー バイオテクノロジーズ，エルエルシー 凍結乾燥容器用充填治具、システム及び使用方法
US20200345658A1 (en) * 2019-05-01 2020-11-05 Southwest Research Institute Compositions Of Dimethyl Trisulfide (DMTS) As A Cyanide Antidote
IL272145A (en) * 2020-01-20 2021-07-29 Stem Cell Medicine Ltd Cosmetic preparations with protein concentrate from a conditioned growth medium of stem cells from adipose tissue

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3717708A (en) * 1968-10-24 1973-02-20 Cutter Lab Blood coagulation complex
US4364861A (en) 1980-05-27 1982-12-21 Cutter Laboratories, Inc. Blood-coagulation-promoting products and methods of preparing them
US6372716B1 (en) 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
PT2130554E (pt) 1999-02-22 2012-11-19 Univ Connecticut Formulações de factor viii isentas de albumina
US20010031721A1 (en) * 1999-05-05 2001-10-18 Chandra Webb Highly concentrated, lyophilized, and liquid factor IX formulations
IL155002A0 (en) * 2000-10-12 2003-10-31 Genentech Inc Reduced-viscosity concentrated protein formulations
AU2004298789A1 (en) 2003-12-19 2005-06-30 Novo Nordisk Health Care Ag Stabilised compositions of factor VII polypeptides
BRPI0509117A (pt) * 2004-03-04 2007-08-28 Wyeth Corp método de liofilização para melhorar a cristalização de excipientes
EP1942868B2 (en) 2005-11-01 2023-10-04 Wyeth LLC Sodium chloride solution for drug reconstitution or dilution

Also Published As

Publication number Publication date
LUC00035I2 (es) 2017-12-01
CR9958A (es) 2008-07-29
KR20110128957A (ko) 2011-11-30
EP1942868B2 (en) 2023-10-04
ES2627684T5 (es) 2024-04-29
HUS1700035I1 (hu) 2017-11-28
AU2006308921B2 (en) 2012-07-19
TWI480063B (zh) 2015-04-11
KR101126670B1 (ko) 2012-04-23
PL1942868T3 (pl) 2017-09-29
NO347263B1 (no) 2023-08-14
HK1245090B (zh) 2020-04-09
LUC00035I1 (es) 2017-09-28
US20200338199A1 (en) 2020-10-29
IL190843A0 (en) 2008-11-03
CA2626531C (en) 2011-11-29
EP3593790A1 (en) 2020-01-15
NZ567685A (en) 2011-07-29
US20200138952A1 (en) 2020-05-07
CN101351190A (zh) 2009-01-21
DK1942868T5 (da) 2024-01-08
DK1942868T3 (en) 2017-06-26
EP3225233A1 (en) 2017-10-04
ES2749574T3 (es) 2020-03-23
EP3225233B1 (en) 2019-08-14
HUE033949T2 (hu) 2018-01-29
NO20082180A (no) 2008-07-04
JP5555425B2 (ja) 2014-07-23
HUS2000003I1 (hu) 2020-02-28
RU2008119514A (ru) 2009-12-10
TW200803915A (en) 2008-01-16
WO2007053533A3 (en) 2007-12-06
PT3225233T (pt) 2019-10-24
WO2007053533A2 (en) 2007-05-10
AU2006308921A1 (en) 2007-05-10
SI1942868T2 (sl) 2023-12-29
PL1942868T5 (pl) 2023-12-27
FI1942868T4 (fi) 2023-10-12
HUE045421T2 (hu) 2019-12-30
EP1942868A2 (en) 2008-07-16
PE20110803A1 (es) 2011-11-07
BRPI0618133A2 (pt) 2011-08-16
PT1942868T (pt) 2017-06-16
FR20C1005I1 (fr) 2020-03-20
AR112443A2 (es) 2019-10-30
KR20080065689A (ko) 2008-07-14
CA2626531A1 (en) 2007-05-10
RU2432157C2 (ru) 2011-10-27
NO20082180L (no) 2008-07-04
SI1942868T1 (sl) 2017-07-31
GT200800037A (es) 2008-10-01
JP2009513705A (ja) 2009-04-02
DK3225233T3 (da) 2019-10-14
ECSP088485A (es) 2008-06-30
CN101351190B (zh) 2013-01-02
PL3225233T3 (pl) 2019-12-31
US20070135343A1 (en) 2007-06-14
AR056748A1 (es) 2007-10-24
EP1942868B1 (en) 2017-04-19
AU2006308921C1 (en) 2013-01-24
US20170021022A1 (en) 2017-01-26
ES2627684T3 (es) 2017-07-31
UA97234C2 (ru) 2012-01-25
IL190843A (en) 2013-08-29
DK1942868T4 (da) 2023-11-06
MY184364A (en) 2021-04-01
PE20151284A1 (es) 2015-10-05
WO2007053533A8 (en) 2008-07-24
SI3225233T1 (sl) 2019-10-30

Similar Documents

Publication Publication Date Title
PE20070714A1 (es) Solucion de cloruro de sodio para reconstitucion o dilucion de farmaco
Griffin et al. Activated protein C: biased for translation
Alshehri et al. Factor XIII-A: an indispensable “factor” in haemostasis and wound healing
ES2409032T3 (es) Formulaciones liofilizadas de vwf recombinante
KR920700679A (ko) 비(nasal) 전달용 지질부형제와 그 사용법
JPH11130667A (ja) ソフトコンタクトレンズ用の眼科用組成物、ソフトコンタクトレンズの濡れ増強方法およびテルペノイドの吸着抑制方法
CO5170431A1 (es) Preparacion farmaceutica que contiene una de las neurotoxinas botulinicas de clostridium botulinum de los tipos a,b,c,d,e,f, o g, o una mezcla de dos o mas de estas neuroxinas
US9982035B2 (en) Modified serpins for the treatment of bleeding disorders
BRPI0821474B1 (pt) Formulação farmacêutica líquida estável
ES2160803T3 (es) Composicion farmaceutica de aplicacion topica, su procedimiento de produccion y su utilizacion.
BRPI0412241A (pt) formulação para medicamentos de proteìna sem adição de albumina de soro humano (hsa)
AR083034A1 (es) ESTABILIZACION DE INMUNOGLOBULINAS Y OTRAS PROTEINAS MEDIANTE UNA FORMULACION ACUOSA CON CLORURO DE SODIO A pH ACIDO DEBIL A NEUTRO
JP2010513462A (ja) 第ＶＩＩおよび第ＶＩＩａ因子組成物
ECSP034883A (es) Amidas de acidos antranilicos con cadena lateral de heteroarilsulfonilo, procedimiento para su preparacion, su empleo como medicamento o agente de diagnostico, asi como preparados farmaceuticos que las contienen
Fenton et al. Biogenesis of the mitochondrial enzyme methylmalonyl-CoA mutase. Synthesis and processing of a precursor in a cell-free system and in cultured cells.
HRP20230929T1 (hr) Stabilni pripravci semaglutida i njihova upotreba
KR20020060080A (ko) 혈액 응고 제ⅶ 인자를 활성화시키는 프로테아제 또는이의 프로효소의 안정화 액제
US20160129115A1 (en) Formulations of liquid stable antithrombin
Kramzer et al. Preformulation characterization of griffithsin, a biopharmaceutical candidate for HIV prevention
BRPI0510694A (pt) composições farmacêuticas compreendendo ingredientes ativos concentrados encapsuladas em gelatina mole
US20060172920A1 (en) Oxidised lipids as reversal agents for boronic acid drugs
Yong et al. Rethinking coagulation: from enzymatic cascade and cell-based reactions to a convergent model involving innate immune activation
Seested et al. In vivo clearance and metabolism of recombinant activated factor VII (rFVIIa) and its complexes with plasma protease inhibitors in the liver
Liu et al. Cytoprotective properties of novel nonpeptide calpain inhibitors in renal cells
ES2310550T3 (es) Preparacion liquida acuosa de pranoprofeno.

Legal Events

Date Code Title Description
FC Refusal